ID   ERBB2_HUMAN             Reviewed;        1255 AA.
AC   P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   10-MAY-2017, entry version 224.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Metastatic lymph node gene 19 protein;
DE            Short=MLN 19;
DE   AltName: Full=Proto-oncogene Neu;
DE   AltName: Full=Proto-oncogene c-ErbB-2;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER2;
DE   AltName: Full=p185erbB2;
DE   AltName: CD_antigen=CD340;
DE   Flags: Precursor;
GN   Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3003577; DOI=10.1038/319230a0;
RA   Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N.,
RA   Saito T., Toyoshima K.;
RT   "Similarity of protein encoded by the human c-erb-B-2 gene to
RT   epidermal growth factor receptor.";
RL   Nature 319:230-234(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-1170.
RX   PubMed=2999974; DOI=10.1126/science.2999974;
RA   Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J.,
RA   Seeburg P.H., Libermann T.A., Schlessinger J., Francke U.,
RA   Levinson A., Ullrich A.;
RT   "Tyrosine kinase receptor with extensive homology to EGF receptor
RT   shares chromosomal location with neu oncogene.";
RL   Science 230:1132-1139(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND
RP   ALA-1170.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1).
RX   PubMed=3039351; DOI=10.1128/MCB.7.7.2597;
RA   Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.;
RT   "Human HER2 (neu) promoter: evidence for multiple mechanisms for
RT   transcriptional initiation.";
RL   Mol. Cell. Biol. 7:2597-2601(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6).
RC   TISSUE=Fetal brain;
RX   PubMed=24722188; DOI=10.1038/ncomms4650;
RA   Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L.,
RA   Broly M., Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S.,
RA   Tasan M., Lemmens I., Kuang X., Zhao N., Malhotra D., Michaelson J.J.,
RA   Vacic V., Calderwood M.A., Roth F.P., Tavernier J., Horvath S.,
RA   Salehi-Ashtiani K., Korkin D., Sebat J., Hill D.E., Hao T., Vidal M.,
RA   Iakoucheva L.M.;
RT   "Protein interaction network of alternatively spliced isoforms from
RT   brain links genetic risk factors for autism.";
RL   Nat. Commun. 5:3650-3650(2014).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031.
RX   PubMed=2995967; DOI=10.1073/pnas.82.19.6497;
RA   Semba K., Kamata N., Toyoshima K., Yamamoto T.;
RT   "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-
RT   erbB-1/epidermal growth factor-receptor gene and is amplified in a
RT   human salivary gland adenocarcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=2992089; DOI=10.1126/science.2992089;
RA   King C.R., Kraus M.H., Aaronson S.A.;
RT   "Amplification of a novel v-erbB-related gene in a human mammary
RT   carcinoma.";
RL   Science 229:974-976(1985).
RN   [11]
RP   NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170.
RX   PubMed=8104414; DOI=10.1089/dna.1993.12.611;
RA   Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.;
RT   "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2)
RT   gene.";
RL   DNA Cell Biol. 12:611-615(1993).
RN   [12]
RP   INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A.
RX   PubMed=10358079; DOI=10.1074/jbc.274.24.17209;
RA   Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.;
RT   "ErbB receptor-induced activation of stat transcription factors is
RT   mediated by Src tyrosine kinases.";
RL   J. Biol. Chem. 274:17209-17218(1999).
RN   [13]
RP   IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A
RP   COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B.
RX   PubMed=10805725; DOI=10.1128/MCB.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of
RT   activated polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [14]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012;
RA   Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z.,
RA   Ali-Seyed M., Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K.,
RA   Hung M.C.;
RT   "Binding at and transactivation of the COX-2 promoter by nuclear
RT   tyrosine kinase receptor ErbB-2.";
RL   Cancer Cell 6:251-261(2004).
RN   [16]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=15210733; DOI=10.1083/jcb.200312094;
RA   Swiercz J.M., Kuner R., Offermanns S.;
RT   "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor
RT   tyrosine kinase ErbB-2.";
RL   J. Cell Biol. 165:869-880(2004).
RN   [17]
RP   INTERACTION WITH MEMO1.
RX   PubMed=15156151; DOI=10.1038/ncb1134;
RA   Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.;
RT   "Memo mediates ErbB2-driven cell motility.";
RL   Nat. Cell Biol. 6:515-522(2004).
RN   [18]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION
RP   WITH KPNB1; RANBP2; CRM1; EEA1 AND CLTC.
RX   PubMed=16314522; DOI=10.1128/MCB.25.24.11005-11018.2005;
RA   Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G.,
RA   Wang S.C., Hung M.C.;
RT   "Endosomal transport of ErbB-2: mechanism for nuclear entry of the
RT   cell surface receptor.";
RL   Mol. Cell. Biol. 25:11005-11018(2005).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [20]
RP   FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712.
RX   PubMed=16794579; DOI=10.1038/sj.emboj.7601191;
RA   Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B.,
RA   Todo F.R., Baselga J., Arribas J.;
RT   "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative
RT   initiation of translation.";
RL   EMBO J. 25:3234-3244(2006).
RN   [21]
RP   INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS.
RX   PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020;
RA   Li Z., Mei Y., Liu X., Zhou M.;
RT   "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor
RT   heterodimer partners.";
RL   Cell. Signal. 19:466-471(2007).
RN   [22]
RP   PHOSPHORYLATION AT TYR-1248.
RX   PubMed=17554007; DOI=10.1523/JNEUROSCI.5381-06.2007;
RA   Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A.,
RA   Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L.,
RA   Offermanns S., Kuner R.;
RT   "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration
RT   and patterning of the developing nervous system in vivo.";
RL   J. Neurosci. 27:6333-6347(2007).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   INTERACTION WITH PTK6, AND ENZYME REGULATION.
RX   PubMed=18719096; DOI=10.1073/pnas.0805009105;
RA   Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M.,
RA   Miller W.T., Muthuswamy S.K.;
RT   "Brk is coamplified with ErbB2 to promote proliferation in breast
RT   cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008).
RN   [26]
RP   FUNCTION IN NUCLEUS.
RX   PubMed=19372587; DOI=10.1158/1541-7786.MCR-08-0316;
RA   Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.;
RT   "ErbB2-mediated Src and signal transducer and activator of
RT   transcription 3 activation leads to transcriptional up-regulation of
RT   p21Cip1 and chemoresistance in breast cancer cells.";
RL   Mol. Cancer Res. 7:592-600(2009).
RN   [27]
RP   INTERACTION WITH CPNE3.
RX   PubMed=20010870; DOI=10.1038/onc.2009.456;
RA   Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R.,
RA   Lienhard S., Duss S., Hofsteenge J., Hynes N.E.;
RT   "Copine-III interacts with ErbB2 and promotes tumor cell migration.";
RL   Oncogene 29:1598-1610(2010).
RN   [28]
RP   FUNCTION.
RX   PubMed=20937854; DOI=10.1073/pnas.1000975107;
RA   Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.;
RT   "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the
RT   plasma membrane of migrating cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   CHROMOSOMAL REARRANGEMENT WITH CDK12.
RX   PubMed=21097718; DOI=10.1158/0008-5472.CAN-10-1749;
RA   Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D.,
RA   Ler L.D., Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A.,
RA   Grabsch H., Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.;
RT   "Genetic and structural variation in the gastric cancer kinome
RT   revealed through targeted deep sequencing.";
RL   Cancer Res. 71:29-39(2011).
RN   [31]
RP   FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21555369; DOI=10.1158/0008-5472.CAN-10-3504;
RA   Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H.,
RA   Chen H.Y., Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P.,
RA   Lien H.C., Tsai C.H., Hung M.C.;
RT   "Nuclear ErbB2 enhances translation and cell growth by activating
RT   transcription of ribosomal RNA genes.";
RL   Cancer Res. 71:4269-4279(2011).
RN   [32]
RP   INTERACTION WITH EGFR.
RX   PubMed=21190959; DOI=10.1210/en.2010-0940;
RA   Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N.,
RA   Qiu X., Kumar U.;
RT   "Dissociation of epidermal growth factor receptor and ErbB2
RT   heterodimers in the presence of somatostatin receptor 5 modulate
RT   signaling pathways.";
RL   Endocrinology 152:931-945(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182; SER-1054; SER-1083
RP   AND THR-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   INTERACTION WITH HSP90AA1 AND HSP90AB1.
RX   PubMed=26517842; DOI=10.1371/journal.pone.0141786;
RA   Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K.,
RA   Rivas C., Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T.,
RA   Beebe K., Trepel J.B., Neckers L.;
RT   "Client proteins and small molecule inhibitors display distinct
RT   binding preferences for constitutive and stress-induced HSP90 isoforms
RT   and their conformationally restricted mutants.";
RL   PLoS ONE 10:E0141786-E0141786(2015).
RN   [37]
RP   PHOSPHORYLATION AT TYR-1112; TYR-1139; TYR-1196 AND TYR-1248, AND
RP   DEPHOSPHORYLATION BY PTPN12.
RX   PubMed=27134172; DOI=10.1016/j.celrep.2016.04.016;
RA   Li H., Yang F., Liu C., Xiao P., Xu Y., Liang Z., Liu C., Wang H.,
RA   Wang W., Zheng W., Zhang W., Ma X., He D., Song X., Cui F., Xu Z.,
RA   Yi F., Sun J.P., Yu X.;
RT   "Crystal structure and substrate specificity of PTPN12.";
RL   Cell Rep. 15:1345-1358(2016).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA
RP   AND BETA-2 MICROGLOBULIN.
RX   PubMed=10593938; DOI=10.1074/jbc.274.51.36422;
RA   Kuhns J.J., Batalia M.A., Yan S., Collins E.J.;
RT   "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a
RT   lack of interactions with the center of the peptide.";
RL   J. Biol. Chem. 274:36422-36427(1999).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH
RP   ERBIN, AND INTERACTION WITH ERBIN.
RX   PubMed=12444095; DOI=10.1074/jbc.C200571200;
RA   Birrane G., Chung J., Ladias J.A.;
RT   "Novel mode of ligand recognition by the Erbin PDZ domain.";
RL   J. Biol. Chem. 278:1399-1402(2003).
RN   [40]
RP   STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION
RP   WITH GRB7.
RX   PubMed=12975581; DOI=10.1023/A:1025498409113;
RA   Ivancic M., Daly R.J., Lyons B.A.;
RT   "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex
RT   and structural basis for Grb7 binding to ErbB2.";
RL   J. Biomol. NMR 27:205-219(2003).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE
RP   ANTIBODY HERCEPTIN.
RX   PubMed=12610629; DOI=10.1038/nature01392;
RA   Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B.,
RA   Denney D.W. Jr., Leahy D.J.;
RT   "Structure of the extracellular region of HER2 alone and in complex
RT   with the Herceptin Fab.";
RL   Nature 421:756-760(2003).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE
RP   ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF
RP   317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187;
RP   ASN-259 AND ASN-530.
RX   PubMed=15093539; DOI=10.1016/S1535-6108(04)00083-2;
RA   Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M.,
RA   Sliwkowski M.X.;
RT   "Insights into ErbB signaling from the structure of the ErbB2-
RT   pertuzumab complex.";
RL   Cancer Cell 5:317-328(2004).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE
RP   ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND
RP   ASN-530.
RX   PubMed=19299620; DOI=10.1126/science.1165480;
RA   Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K.,
RA   Man W., Peale F., Ross S., Wiesmann C., Fuh G.;
RT   "Variants of the antibody herceptin that interact with HER2 and VEGF
RT   at the antigen binding site.";
RL   Science 323:1610-1614(2009).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH
RP   ENGINEERED ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT
RP   ASN-68; ASN-259 AND ASN-571.
RX   PubMed=20696930; DOI=10.1073/pnas.1005025107;
RA   Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.;
RT   "Structural basis for high-affinity HER2 receptor binding by an
RT   engineered protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH
RP   INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ENZYME
RP   REGULATION.
RX   PubMed=21454582; DOI=10.1074/jbc.M110.206193;
RA   Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G.,
RA   Jennings A., Iwamoto K., Habuka N., Hirokawa A., Ishikawa T.,
RA   Tanaka T., Miki H., Ohta Y., Sogabe S.;
RT   "Structural analysis of the mechanism of inhibition and allosteric
RT   activation of the kinase domain of HER2 protein.";
RL   J. Biol. Chem. 286:18756-18765(2011).
RN   [46]
RP   VARIANTS VAL-654 AND VAL-655.
RX   PubMed=8095488; DOI=10.1006/geno.1993.1081;
RA   Ehsani A., Low J., Wallace R.B., Wu A.M.;
RT   "Characterization of a new allele of the human ERBB2 gene by allele-
RT   specific competition hybridization.";
RL   Genomics 15:426-429(1993).
RN   [47]
RP   INVOLVEMENT IN CANCER, VARIANT GASC SER-776, VARIANT OC SER-857,
RP   VARIANT GLM LYS-914, AND VARIANTS LNCR PRO-755; ALA-TYR-VAL-MET-774
RP   INS AND VAL-GLY-SER-779 INS.
RX   PubMed=15457249; DOI=10.1038/431525b;
RG   Cancer genome project and collaborative group;
RA   Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J.,
RA   Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M.,
RA   Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A.,
RA   Drozd A., Edwards K., Forbes S., Foster R., Gray K., Greenman C.,
RA   Halliday K., Hills K., Kosmidou V., Lugg R., Menzies A., Perry J.,
RA   Petty R., Raine K., Ratford L., Shepherd R., Small A., Stephens Y.,
RA   Tofts C., Varian J., West S., Widaa S., Yates A., Brasseur F.,
RA   Cooper C.S., Flanagan A.M., Knowles M., Leung S.Y., Louis D.N.,
RA   Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.,
RA   Chenevix-Trench G., Weber B.L., Yuen S.T., Harris G., Goldstraw P.,
RA   Nicholson A.G., Futreal P.A., Wooster R., Stratton M.R.;
RT   "Lung cancer: intragenic ERBB2 kinase mutations in tumours.";
RL   Nature 431:525-526(2004).
RN   [48]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170
RP   AND ASP-1216, VARIANT GASC SER-776, AND VARIANT OC SER-857.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein tyrosine kinase that is part of several cell
CC       surface receptor complexes, but that apparently needs a coreceptor
CC       for ligand binding. Essential component of a neuregulin-receptor
CC       complex, although neuregulins do not interact with it alone. GP30
CC       is a potential ligand for this receptor. Regulates outgrowth and
CC       stabilization of peripheral microtubules (MTs). Upon ERBB2
CC       activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the
CC       phosphorylation and thus the inhibition of GSK3B at cell membrane.
CC       This prevents the phosphorylation of APC and CLASP2, allowing its
CC       association with the cell membrane. In turn, membrane-bound APC
CC       allows the localization of MACF1 to the cell membrane, which is
CC       required for microtubule capture and stabilization. {ECO:0000305}.
CC   -!- FUNCTION: In the nucleus is involved in transcriptional
CC       regulation. Associates with the 5'-TCAAATTC-3' sequence in the
CC       PTGS2/COX-2 promoter and activates its transcription. Implicated
CC       in transcriptional activation of CDKN1A; the function involves
CC       STAT3 and SRC. Involved in the transcription of rRNA genes by RNA
CC       Pol I and enhances protein synthesis and cell growth.
CC       {ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:15380516,
CC       ECO:0000269|PubMed:21555369}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:21454582}.
CC   -!- ENZYME REGULATION: Activated by dimerization. Not activated by
CC       EGF, TGF-alpha and amphiregulin. Interaction with PTK6 increases
CC       its intrinsic kinase activity. {ECO:0000269|PubMed:18719096,
CC       ECO:0000269|PubMed:21454582}.
CC   -!- SUBUNIT: Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3
CC       and ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:21190959,
CC       PubMed:16978839). Part of a complex with EGFR and either PIK3C2A
CC       or PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-
CC       1196 (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733).
CC       Interacts (when phosphorylated on Tyr-1248) with MEMO1
CC       (PubMed:15156151). Interacts with MUC1; the interaction is
CC       enhanced by heregulin (HRG) (PubMed:12939402). Interacts (when
CC       phosphorylated on Tyr-1139) with GRB7 (via SH2 domain)
CC       (PubMed:12975581). Interacts (when phosphorylated on Tyr-1248)
CC       with ERBIN (PubMed:12444095). Interacts with KPNB1, RANBP2, EEA1,
CC       CRM1 and CLTC (PubMed:16314522). Interacts with PTK6
CC       (PubMed:18719096). Interacts with RPA194 and ACTB
CC       (PubMed:21555369). Interacts with PRKCABP, SRC and MYOC (By
CC       similarity). Interacts (preferentially with the tyrosine
CC       phosphorylated form) with CPNE3; this interaction occurs at the
CC       cell membrane and is increased in a growth factor heregulin-
CC       dependent manner (PubMed:20010870). Interacts with HSP90AA1 and
CC       HSP90AB1 in an ATP-dependent manner; the interaction suppresses
CC       ERBB2 kinase activity (PubMed:26517842).
CC       {ECO:0000250|UniProtKB:P70424, ECO:0000269|PubMed:10358079,
CC       ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:12939402,
CC       ECO:0000269|PubMed:12975581, ECO:0000269|PubMed:15093539,
CC       ECO:0000269|PubMed:15156151, ECO:0000269|PubMed:15210733,
CC       ECO:0000269|PubMed:16314522, ECO:0000269|PubMed:16978839,
CC       ECO:0000269|PubMed:18719096, ECO:0000269|PubMed:20010870,
CC       ECO:0000269|PubMed:21190959, ECO:0000269|PubMed:21454582,
CC       ECO:0000269|PubMed:21555369, ECO:0000269|PubMed:26517842}.
CC   -!- INTERACTION:
CC       Self; NbExp=9; IntAct=EBI-641062, EBI-641062;
CC       P00519:ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543;
CC       P42684:ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694;
CC       P15309:ACPP; NbExp=3; IntAct=EBI-641062, EBI-1222012;
CC       P60709:ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944;
CC       Q92625:ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612;
CC       O00213:APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694;
CC       O75815:BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336;
CC       Q16543:CDC37; NbExp=3; IntAct=EBI-641062, EBI-295634;
CC       Q9NSE2:CISH; NbExp=4; IntAct=EBI-641062, EBI-617866;
CC       Q7Z7G1:CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194;
CC       P46109:CRKL; NbExp=2; IntAct=EBI-641062, EBI-910;
CC       Q99704:DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360;
CC       Q8TEW6:DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542;
CC       Q15075:EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113;
CC       P98172:EFNB1; NbExp=11; IntAct=EBI-641062, EBI-538287;
CC       P00533:EGFR; NbExp=21; IntAct=EBI-641062, EBI-297353;
CC       P21860:ERBB3; NbExp=25; IntAct=EBI-641062, EBI-720706;
CC       Q15303:ERBB4; NbExp=3; IntAct=EBI-641062, EBI-80371;
CC       Q9UJM3:ERRFI1; NbExp=3; IntAct=EBI-641062, EBI-2941912;
CC       P09769:FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732;
CC       P06241:FYN; NbExp=2; IntAct=EBI-641062, EBI-515315;
CC       O75791:GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418;
CC       P62993:GRB2; NbExp=4; IntAct=EBI-641062, EBI-401755;
CC       Q14451:GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191;
CC       O75367:H2AFY; NbExp=6; IntAct=EBI-641062, EBI-2868511;
CC       O75367-3:H2AFY; NbExp=3; IntAct=EBI-641062, EBI-6250866;
CC       P07900:HSP90AA1; NbExp=4; IntAct=EBI-641062, EBI-296047;
CC       P08238:HSP90AB1; NbExp=3; IntAct=EBI-641062, EBI-352572;
CC       P46940:IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509;
CC       P35568:IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592;
CC       Q08881:ITK; NbExp=2; IntAct=EBI-641062, EBI-968552;
CC       P23458:JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438;
CC       Q14974:KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758;
CC       Q9UQF2:MAPK8IP1; NbExp=3; IntAct=EBI-641062, EBI-78404;
CC       Q13387:MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813;
CC       P42679:MATK; NbExp=2; IntAct=EBI-641062, EBI-751664;
CC       Q9Y316:MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635;
CC       Q02297-7:NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927;
CC       O00750:PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107;
CC       P27986:PIK3R1; NbExp=11; IntAct=EBI-641062, EBI-79464;
CC       O00459:PIK3R2; NbExp=6; IntAct=EBI-641062, EBI-346930;
CC       Q92569:PIK3R3; NbExp=9; IntAct=EBI-641062, EBI-79893;
CC       P19174:PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387;
CC       P16885:PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403;
CC       O95602:POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472;
CC       Q05397:PTK2; NbExp=2; IntAct=EBI-641062, EBI-702142;
CC       Q13882:PTK6; NbExp=2; IntAct=EBI-641062, EBI-1383632;
CC       Q06124:PTPN11; NbExp=2; IntAct=EBI-641062, EBI-297779;
CC       Q05209:PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035;
CC       Q99952:PTPN18; NbExp=6; IntAct=EBI-641062, EBI-1384210;
CC       Q99952-1:PTPN18; NbExp=5; IntAct=EBI-641062, EBI-12739708;
CC       P23467:PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766;
CC       P08575:PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341;
CC       Q12913:PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500;
CC       Q15262:PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052;
CC       Q16827:PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739;
CC       P49792:RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138;
CC       P20936:RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476;
CC       O95980:RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742;
CC       Q9NP31:SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630;
CC       P29353:SHC1; NbExp=9; IntAct=EBI-641062, EBI-78835;
CC       P98077:SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023;
CC       Q92529:SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084;
CC       Q9H6Q3:SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854;
CC       O15524:SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198;
CC       P12931:SRC; NbExp=11; IntAct=EBI-641062, EBI-621482;
CC       P42224:STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697;
CC       P40763:STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675;
CC       Q7KZ85:SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547;
CC       P43405:SYK; NbExp=7; IntAct=EBI-641062, EBI-78302;
CC       Q9Y490:TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036;
CC       Q63HR2:TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488;
CC       Q96D37:VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353;
CC       P52735:VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549;
CC       O14980:XPO1; NbExp=2; IntAct=EBI-641062, EBI-355867;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasm, perinuclear region. Nucleus.
CC       Note=Translocation to the nucleus requires endocytosis, probably
CC       endosomal sorting and is mediated by importin beta-1/KPNB1.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=6;
CC       Name=1; Synonyms=ERBB2, HER2;
CC         IsoId=P04626-1; Sequence=Displayed;
CC       Name=2; Synonyms=CTF-611;
CC         IsoId=P04626-2; Sequence=VSP_039249;
CC         Note=Produced by alternative initiation at Met-611 of isoform
CC         1.;
CC       Name=3; Synonyms=CTF-687;
CC         IsoId=P04626-3; Sequence=VSP_039250;
CC         Note=Produced by alternative initiation at Met-687 of isoform
CC         1.;
CC       Name=4;
CC         IsoId=P04626-4; Sequence=VSP_039248;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=5;
CC         IsoId=P04626-5; Sequence=VSP_054787;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on partial mRNA and EST data.;
CC       Name=6; Synonyms=B;
CC         IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904;
CC   -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues
CC       including primary breast tumors and tumors from small bowel,
CC       esophagus, kidney and mouth. {ECO:0000269|PubMed:15380516}.
CC   -!- PTM: Autophosphorylated. Autophosphorylation occurs in trans, i.e.
CC       one subunit of the dimeric receptor phosphorylates tyrosine
CC       residues on the other subunit (Probable). Ligand-binding increases
CC       phosphorylation on tyrosine residues (PubMed:27134172). Signaling
CC       via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007).
CC       Dephosphorylated by PTPN12 (PubMed:27134172).
CC       {ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:27134172,
CC       ECO:0000305}.
CC   -!- POLYMORPHISM: There are four alleles due to the variations in
CC       positions 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency
CC       of 0.782; allele B2 (Ile-654/Val-655) has a frequency of 0.206;
CC       allele B3 (Val-654/Val-655) has a frequency of 0.012.
CC   -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or
CC       malignant central nervous system neoplasms derived from glial
CC       cells. They comprise astrocytomas and glioblastoma multiforme that
CC       are derived from astrocytes, oligodendrogliomas derived from
CC       oligodendrocytes and ependymomas derived from ependymocytes.
CC       {ECO:0000269|PubMed:15457249}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer
CC       defines malignancies originating from ovarian tissue. Although
CC       many histologic types of ovarian tumors have been described,
CC       epithelial ovarian carcinoma is the most common form. Ovarian
CC       cancers are often asymptomatic and the recognized signs and
CC       symptoms, even of late-stage disease, are vague. Consequently,
CC       most patients are diagnosed with advanced disease.
CC       {ECO:0000269|PubMed:15457249, ECO:0000269|PubMed:17344846}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy
CC       affecting tissues of the lung. The most common form of lung cancer
CC       is non-small cell lung cancer (NSCLC) that can be divided into 3
CC       major histologic subtypes: squamous cell carcinoma,
CC       adenocarcinoma, and large cell lung cancer. NSCLC is often
CC       diagnosed at an advanced stage and has a poor prognosis.
CC       {ECO:0000269|PubMed:15457249}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease
CC       which starts in the stomach, can spread to the esophagus or the
CC       small intestine, and can extend through the stomach wall to nearby
CC       lymph nodes and organs. It also can metastasize to other parts of
CC       the body. The term gastric cancer or gastric carcinoma refers to
CC       adenocarcinoma of the stomach that accounts for most of all
CC       gastric malignant tumors. Two main histologic types are
CC       recognized, diffuse type and intestinal type carcinomas. Diffuse
CC       tumors are poorly differentiated infiltrating lesions, resulting
CC       in thickening of the stomach. In contrast, intestinal tumors are
CC       usually exophytic, often ulcerating, and associated with
CC       intestinal metaplasia of the stomach, most often observed in
CC       sporadic disease. {ECO:0000269|PubMed:15457249,
CC       ECO:0000269|PubMed:17344846}. Note=The protein represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a
CC       cause gastric cancer. Deletions within 17q12 region producing
CC       fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion
CC       leading to truncated CDK12 protein not in-frame with ERBB2.
CC       {ECO:0000269|PubMed:21097718}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ERBB2ID162ch17q11.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/erbb2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry;
CC       URL="https://en.wikipedia.org/wiki/ERBB2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AH001455; AAA35808.1; -; Genomic_DNA.
DR   EMBL; X03363; CAA27060.1; -; mRNA.
DR   EMBL; M11730; AAA75493.1; -; mRNA.
DR   EMBL; M12036; AAA35978.1; -; Genomic_DNA.
DR   EMBL; AY208911; AAO18082.1; -; Genomic_DNA.
DR   EMBL; AK295195; BAG58195.1; -; mRNA.
DR   EMBL; CH471152; EAW60597.1; -; Genomic_DNA.
DR   EMBL; BC167147; AAI67147.1; -; mRNA.
DR   EMBL; M16792; AAA58637.1; -; Genomic_DNA.
DR   EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; KJ534964; AHW56604.1; -; mRNA.
DR   EMBL; L29395; AAA35809.1; -; Genomic_DNA.
DR   EMBL; M95667; AAC37531.1; -; Genomic_DNA.
DR   CCDS; CCDS32642.1; -. [P04626-1]
DR   CCDS; CCDS45667.1; -. [P04626-5]
DR   CCDS; CCDS74052.1; -. [P04626-4]
DR   PIR; A24571; A24571.
DR   RefSeq; NP_001005862.1; NM_001005862.2. [P04626-5]
DR   RefSeq; NP_001276865.1; NM_001289936.1. [P04626-4]
DR   RefSeq; NP_001276867.1; NM_001289938.1.
DR   RefSeq; NP_004439.2; NM_004448.3. [P04626-1]
DR   UniGene; Hs.446352; -.
DR   PDB; 1MFG; X-ray; 1.25 A; B=1247-1255.
DR   PDB; 1MFL; X-ray; 1.88 A; B=1247-1255.
DR   PDB; 1MW4; NMR; -; B=1135-1144.
DR   PDB; 1N8Z; X-ray; 2.52 A; C=23-629.
DR   PDB; 1OVC; Model; -; A=737-1031.
DR   PDB; 1QR1; X-ray; 2.40 A; C/F=654-662.
DR   PDB; 1S78; X-ray; 3.25 A; A/B=23-646.
DR   PDB; 2A91; X-ray; 2.50 A; A=22-530.
DR   PDB; 2JWA; NMR; -; A/B=641-684.
DR   PDB; 2KS1; NMR; -; A=641-684.
DR   PDB; 2L4K; NMR; -; B=1135-1144.
DR   PDB; 2N2A; NMR; -; A/B=644-700.
DR   PDB; 3BE1; X-ray; 2.90 A; A=23-646.
DR   PDB; 3H3B; X-ray; 2.45 A; A/B=23-214.
DR   PDB; 3MZW; X-ray; 2.90 A; A=23-646.
DR   PDB; 3N85; X-ray; 3.20 A; A=23-646.
DR   PDB; 3PP0; X-ray; 2.25 A; A/B=703-1009.
DR   PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028.
DR   PDB; 3WLW; X-ray; 3.09 A; A/B=23-586.
DR   PDB; 3WSQ; X-ray; 3.50 A; A=23-586.
DR   PDB; 4GFU; X-ray; 2.00 A; F=1246-1252.
DR   PDB; 4HRL; X-ray; 2.55 A; C=24-219.
DR   PDB; 4HRM; X-ray; 3.20 A; A/C=24-219.
DR   PDB; 4HRN; X-ray; 2.65 A; C/D=529-625.
DR   PDBsum; 1MFG; -.
DR   PDBsum; 1MFL; -.
DR   PDBsum; 1MW4; -.
DR   PDBsum; 1N8Z; -.
DR   PDBsum; 1OVC; -.
DR   PDBsum; 1QR1; -.
DR   PDBsum; 1S78; -.
DR   PDBsum; 2A91; -.
DR   PDBsum; 2JWA; -.
DR   PDBsum; 2KS1; -.
DR   PDBsum; 2L4K; -.
DR   PDBsum; 2N2A; -.
DR   PDBsum; 3BE1; -.
DR   PDBsum; 3H3B; -.
DR   PDBsum; 3MZW; -.
DR   PDBsum; 3N85; -.
DR   PDBsum; 3PP0; -.
DR   PDBsum; 3RCD; -.
DR   PDBsum; 3WLW; -.
DR   PDBsum; 3WSQ; -.
DR   PDBsum; 4GFU; -.
DR   PDBsum; 4HRL; -.
DR   PDBsum; 4HRM; -.
DR   PDBsum; 4HRN; -.
DR   ProteinModelPortal; P04626; -.
DR   SMR; P04626; -.
DR   BioGrid; 108376; 176.
DR   DIP; DIP-8N; -.
DR   IntAct; P04626; 248.
DR   MINT; MINT-158636; -.
DR   STRING; 9606.ENSP00000269571; -.
DR   BindingDB; P04626; -.
DR   ChEMBL; CHEMBL1824; -.
DR   DrugBank; DB08916; Afatinib.
DR   DrugBank; DB04988; IGN311.
DR   DrugBank; DB01259; Lapatinib.
DR   DrugBank; DB06366; Pertuzumab.
DR   DrugBank; DB00072; Trastuzumab.
DR   DrugBank; DB05773; Trastuzumab emtansine.
DR   DrugBank; DB05007; XL647.
DR   GuidetoPHARMACOLOGY; 2019; -.
DR   iPTMnet; P04626; -.
DR   PhosphoSitePlus; P04626; -.
DR   BioMuta; ERBB2; -.
DR   DMDM; 119533; -.
DR   EPD; P04626; -.
DR   PaxDb; P04626; -.
DR   PeptideAtlas; P04626; -.
DR   PRIDE; P04626; -.
DR   DNASU; 2064; -.
DR   Ensembl; ENST00000269571; ENSP00000269571; ENSG00000141736. [P04626-1]
DR   Ensembl; ENST00000406381; ENSP00000385185; ENSG00000141736. [P04626-5]
DR   Ensembl; ENST00000541774; ENSP00000446466; ENSG00000141736. [P04626-4]
DR   Ensembl; ENST00000584601; ENSP00000462438; ENSG00000141736. [P04626-5]
DR   GeneID; 2064; -.
DR   KEGG; hsa:2064; -.
DR   UCSC; uc060esv.1; human. [P04626-1]
DR   CTD; 2064; -.
DR   DisGeNET; 2064; -.
DR   GeneCards; ERBB2; -.
DR   HGNC; HGNC:3430; ERBB2.
DR   HPA; CAB000043; -.
DR   HPA; CAB020416; -.
DR   HPA; CAB062555; -.
DR   HPA; HPA001060; -.
DR   HPA; HPA001338; -.
DR   HPA; HPA001383; -.
DR   MalaCards; ERBB2; -.
DR   MIM; 137800; phenotype.
DR   MIM; 164870; gene.
DR   MIM; 167000; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 613659; phenotype.
DR   neXtProt; NX_P04626; -.
DR   OpenTargets; ENSG00000141736; -.
DR   PharmGKB; PA27844; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   eggNOG; ENOG410XNSR; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000230982; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P04626; -.
DR   KO; K05083; -.
DR   OMA; ACYPLCA; -.
DR   OrthoDB; EOG091G00NO; -.
DR   PhylomeDB; P04626; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors.
DR   SignaLink; P04626; -.
DR   SIGNOR; P04626; -.
DR   ChiTaRS; ERBB2; human.
DR   EvolutionaryTrace; P04626; -.
DR   GeneWiki; HER2/neu; -.
DR   GenomeRNAi; 2064; -.
DR   PMAP-CutDB; P04626; -.
DR   PRO; PR:P04626; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141736; -.
DR   CleanEx; HS_ERBB2; -.
DR   ExpressionAtlas; P04626; baseline and differential.
DR   Genevisible; P04626; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; NAS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB.
DR   GO; GO:0004716; F:signal transducer, downstream of receptor, with protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0007167; P:enzyme linked receptor protein signaling pathway; TAS:ProtInc.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:1901185; P:negative regulation of ERBB signaling pathway; TAS:Reactome.
DR   GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0007422; P:peripheral nervous system development; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB.
DR   GO; GO:0045943; P:positive regulation of transcription from RNA polymerase I promoter; IMP:UniProtKB.
DR   GO; GO:0045945; P:positive regulation of transcription from RNA polymerase III promoter; IDA:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:Reactome.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IDA:BHF-UCL.
DR   Gene3D; 3.80.20.20; -; 3.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative initiation; Alternative splicing;
KW   ATP-binding; Cell membrane; Chromosomal rearrangement;
KW   Complete proteome; Cytoplasm; Disulfide bond; Glycoprotein; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Signal; Transcription;
KW   Transcription regulation; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23   1255       Receptor tyrosine-protein kinase erbB-2.
FT                                /FTId=PRO_0000016669.
FT   TOPO_DOM     23    652       Extracellular. {ECO:0000255}.
FT   TRANSMEM    653    675       Helical. {ECO:0000255}.
FT   TOPO_DOM    676   1255       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      720    987       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     726    734       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      676    689       Required for interaction with KPNB1 and
FT                                EEA1. {ECO:0000269|PubMed:16314522}.
FT   REGION     1195   1197       Interaction with PIK3C2B. {ECO:0000305}.
FT   MOTIF       676    689       Nuclear localization signal.
FT   ACT_SITE    845    845       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     753    753       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     182    182       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1054   1054       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1078   1078       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06494}.
FT   MOD_RES    1083   1083       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1107   1107       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1112   1112       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:27134172}.
FT   MOD_RES    1139   1139       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:27134172}.
FT   MOD_RES    1151   1151       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1166   1166       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1196   1196       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:27134172}.
FT   MOD_RES    1248   1248       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000269|PubMed:17554007,
FT                                ECO:0000269|PubMed:27134172}.
FT   CARBOHYD     68     68       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000269|PubMed:20696930}.
FT   CARBOHYD    124    124       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    187    187       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3N85, ECO:0000255}.
FT   CARBOHYD    259    259       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000269|PubMed:15093539,
FT                                ECO:0000269|PubMed:19299620,
FT                                ECO:0000269|PubMed:20696930}.
FT   CARBOHYD    530    530       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:1S78,
FT                                ECO:0000269|PubMed:15093539,
FT                                ECO:0000269|PubMed:19299620}.
FT   CARBOHYD    571    571       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:3MZW,
FT                                ECO:0000269|PubMed:20696930}.
FT   CARBOHYD    629    629       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     26     53       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3H3B,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRL,
FT                                ECO:0000244|PDB:4HRM}.
FT   DISULFID    162    192       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3H3B,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRL,
FT                                ECO:0000244|PDB:4HRM}.
FT   DISULFID    195    204       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3H3B,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRL,
FT                                ECO:0000244|PDB:4HRM}.
FT   DISULFID    199    212       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3H3B,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRL,
FT                                ECO:0000244|PDB:4HRM}.
FT   DISULFID    220    227       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    224    235       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    236    244       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    240    252       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    255    264       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    268    295       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    299    311       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    315    331       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    334    338       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    342    367       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    475    504       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    511    520       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    515    528       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:2A91,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ}.
FT   DISULFID    531    540       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRN}.
FT   DISULFID    544    560       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRN}.
FT   DISULFID    563    576       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRN}.
FT   DISULFID    567    584       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:3WLW,
FT                                ECO:0000244|PDB:3WSQ,
FT                                ECO:0000244|PDB:4HRN}.
FT   DISULFID    587    596       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:1S78,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3MZW,
FT                                ECO:0000244|PDB:3N85,
FT                                ECO:0000244|PDB:4HRN}.
FT   DISULFID    600    623       {ECO:0000244|PDB:1N8Z,
FT                                ECO:0000244|PDB:3BE1,
FT                                ECO:0000244|PDB:3N85}.
FT   DISULFID    626    634       {ECO:0000244|PDB:3N85}.
FT   DISULFID    630    642       {ECO:0000244|PDB:3N85}.
FT   VAR_SEQ       1    686       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_039250.
FT   VAR_SEQ       1    610       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_039249.
FT   VAR_SEQ       1     30       Missing (in isoform 5). {ECO:0000305}.
FT                                /FTId=VSP_054787.
FT   VAR_SEQ       1     23       MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in
FT                                isoform 4). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_039248.
FT   VAR_SEQ     633    648       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055902.
FT   VAR_SEQ     771    883       AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVR
FT                                ENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVL
FT                                VKSPNHVKITDFGLARLLDIDETEYHADGGK -> TISNLF
FT                                SNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLW
FT                                GCRGEPRVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTR
FT                                AGGSTQHLQRDTYGREPRVPGSGRASVNQKAKSAEALMCPQ
FT                                GAGKA (in isoform 6).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055903.
FT   VAR_SEQ     884   1255       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:24722188}.
FT                                /FTId=VSP_055904.
FT   VARIANT     452    452       W -> C (in dbSNP:rs4252633).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_016317.
FT   VARIANT     654    654       I -> V (in allele B3; dbSNP:rs1801201).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8095488}.
FT                                /FTId=VAR_004077.
FT   VARIANT     655    655       I -> V (in allele B2 and allele B3;
FT                                dbSNP:rs1136201).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8095488,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_004078.
FT   VARIANT     755    755       L -> P (in LNCR; somatic mutation;
FT                                unknown pathological significance;
FT                                dbSNP:rs121913469).
FT                                {ECO:0000269|PubMed:15457249}.
FT                                /FTId=VAR_055432.
FT   VARIANT     768    768       L -> S (in dbSNP:rs56366519).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042097.
FT   VARIANT     774    774       M -> MAYVM (in LNCR; somatic mutation;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:15457249}.
FT                                /FTId=VAR_055433.
FT   VARIANT     776    776       G -> S (in GASC; somatic mutation;
FT                                unknown pathological significance;
FT                                dbSNP:rs28933369).
FT                                {ECO:0000269|PubMed:15457249,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042098.
FT   VARIANT     779    779       S -> SVGS (in LNCR; somatic mutation;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:15457249}.
FT                                /FTId=VAR_055434.
FT   VARIANT     857    857       N -> S (in OC; somatic mutation; unknown
FT                                pathological significance;
FT                                dbSNP:rs28933370).
FT                                {ECO:0000269|PubMed:15457249,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042099.
FT   VARIANT     914    914       E -> K (in GLM; somatic mutation; unknown
FT                                pathological significance;
FT                                dbSNP:rs28933368).
FT                                {ECO:0000269|PubMed:15457249}.
FT                                /FTId=VAR_055435.
FT   VARIANT    1170   1170       P -> A (in dbSNP:rs61552325).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:2999974,
FT                                ECO:0000269|PubMed:8104414,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_016318.
FT   VARIANT    1216   1216       A -> D (in dbSNP:rs55943169).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042100.
FT   MUTAGEN     317    318       LH->AA: Reduces dimerization with ERBB3.
FT                                {ECO:0000269|PubMed:15093539}.
FT   MUTAGEN     611    611       M->A: Prevents synthesis of isoform 2.
FT                                {ECO:0000269|PubMed:16794579}.
FT   MUTAGEN     687    687       M->A: Prevents synthesis of isoform 3.
FT                                {ECO:0000269|PubMed:16794579}.
FT   MUTAGEN     706    706       M->A: No effect on isoform production.
FT                                {ECO:0000269|PubMed:16794579}.
FT   MUTAGEN     712    712       M->A: No effect on isoform production.
FT                                {ECO:0000269|PubMed:16794579}.
FT   STRAND       25     27       {ECO:0000244|PDB:3H3B}.
FT   HELIX        39     50       {ECO:0000244|PDB:3H3B}.
FT   STRAND       54     58       {ECO:0000244|PDB:3H3B}.
FT   STRAND       60     64       {ECO:0000244|PDB:3H3B}.
FT   HELIX        72     74       {ECO:0000244|PDB:3H3B}.
FT   STRAND       79     82       {ECO:0000244|PDB:3H3B}.
FT   STRAND       84     88       {ECO:0000244|PDB:3H3B}.
FT   STRAND       92     95       {ECO:0000244|PDB:3H3B}.
FT   TURN        109    111       {ECO:0000244|PDB:3H3B}.
FT   STRAND      112    117       {ECO:0000244|PDB:3H3B}.
FT   TURN        130    132       {ECO:0000244|PDB:3H3B}.
FT   STRAND      139    141       {ECO:0000244|PDB:3H3B}.
FT   STRAND      150    156       {ECO:0000244|PDB:3H3B}.
FT   TURN        164    166       {ECO:0000244|PDB:3H3B}.
FT   HELIX       169    172       {ECO:0000244|PDB:3H3B}.
FT   HELIX       175    177       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      182    184       {ECO:0000244|PDB:3H3B}.
FT   STRAND      199    202       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      204    208       {ECO:0000244|PDB:3H3B}.
FT   HELIX       209    211       {ECO:0000244|PDB:4HRL}.
FT   STRAND      217    219       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      221    223       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      227    231       {ECO:0000244|PDB:2A91}.
FT   HELIX       232    234       {ECO:0000244|PDB:2A91}.
FT   STRAND      240    248       {ECO:0000244|PDB:2A91}.
FT   STRAND      251    260       {ECO:0000244|PDB:2A91}.
FT   STRAND      263    267       {ECO:0000244|PDB:2A91}.
FT   STRAND      271    274       {ECO:0000244|PDB:2A91}.
FT   TURN        276    278       {ECO:0000244|PDB:2A91}.
FT   STRAND      281    283       {ECO:0000244|PDB:2A91}.
FT   STRAND      289    291       {ECO:0000244|PDB:2A91}.
FT   STRAND      294    298       {ECO:0000244|PDB:2A91}.
FT   STRAND      303    305       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      309    314       {ECO:0000244|PDB:2A91}.
FT   STRAND      320    323       {ECO:0000244|PDB:2A91}.
FT   STRAND      325    327       {ECO:0000244|PDB:3MZW}.
FT   STRAND      329    332       {ECO:0000244|PDB:2A91}.
FT   STRAND      335    337       {ECO:0000244|PDB:2A91}.
FT   HELIX       348    352       {ECO:0000244|PDB:2A91}.
FT   TURN        358    360       {ECO:0000244|PDB:2A91}.
FT   HELIX       361    364       {ECO:0000244|PDB:2A91}.
FT   STRAND      368    376       {ECO:0000244|PDB:2A91}.
FT   HELIX       378    382       {ECO:0000244|PDB:2A91}.
FT   HELIX       385    387       {ECO:0000244|PDB:2A91}.
FT   HELIX       396    402       {ECO:0000244|PDB:2A91}.
FT   STRAND      405    408       {ECO:0000244|PDB:2A91}.
FT   STRAND      410    413       {ECO:0000244|PDB:2A91}.
FT   HELIX       423    425       {ECO:0000244|PDB:2A91}.
FT   STRAND      430    435       {ECO:0000244|PDB:3WLW}.
FT   TURN        438    440       {ECO:0000244|PDB:2A91}.
FT   STRAND      441    447       {ECO:0000244|PDB:2A91}.
FT   STRAND      463    469       {ECO:0000244|PDB:2A91}.
FT   TURN        477    479       {ECO:0000244|PDB:3WLW}.
FT   HELIX       482    485       {ECO:0000244|PDB:2A91}.
FT   STRAND      486    488       {ECO:0000244|PDB:3N85}.
FT   STRAND      493    499       {ECO:0000244|PDB:2A91}.
FT   HELIX       501    506       {ECO:0000244|PDB:2A91}.
FT   TURN        507    509       {ECO:0000244|PDB:3N85}.
FT   HELIX       516    518       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      520    524       {ECO:0000244|PDB:2A91}.
FT   HELIX       525    527       {ECO:0000244|PDB:2A91}.
FT   STRAND      528    536       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      539    542       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      545    551       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      553    556       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      559    562       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      565    567       {ECO:0000244|PDB:3WSQ}.
FT   STRAND      571    573       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      575    580       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      583    592       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      595    599       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      602    604       {ECO:0000244|PDB:3N85}.
FT   STRAND      615    617       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      621    625       {ECO:0000244|PDB:1N8Z}.
FT   STRAND      628    632       {ECO:0000244|PDB:3N85}.
FT   STRAND      635    637       {ECO:0000244|PDB:3N85}.
FT   HELIX       651    678       {ECO:0000244|PDB:2JWA}.
FT   HELIX       684    690       {ECO:0000244|PDB:2N2A}.
FT   HELIX       691    697       {ECO:0000244|PDB:2N2A}.
FT   HELIX       717    719       {ECO:0000244|PDB:3PP0}.
FT   STRAND      720    728       {ECO:0000244|PDB:3PP0}.
FT   STRAND      730    739       {ECO:0000244|PDB:3PP0}.
FT   STRAND      748    755       {ECO:0000244|PDB:3PP0}.
FT   HELIX       761    774       {ECO:0000244|PDB:3PP0}.
FT   STRAND      785    799       {ECO:0000244|PDB:3PP0}.
FT   HELIX       806    812       {ECO:0000244|PDB:3PP0}.
FT   TURN        814    816       {ECO:0000244|PDB:3PP0}.
FT   HELIX       819    838       {ECO:0000244|PDB:3PP0}.
FT   HELIX       848    850       {ECO:0000244|PDB:3PP0}.
FT   STRAND      851    855       {ECO:0000244|PDB:3PP0}.
FT   STRAND      858    861       {ECO:0000244|PDB:3PP0}.
FT   HELIX       886    888       {ECO:0000244|PDB:3PP0}.
FT   HELIX       891    896       {ECO:0000244|PDB:3PP0}.
FT   HELIX       901    916       {ECO:0000244|PDB:3PP0}.
FT   TURN        922    925       {ECO:0000244|PDB:3PP0}.
FT   HELIX       928    930       {ECO:0000244|PDB:3PP0}.
FT   HELIX       931    936       {ECO:0000244|PDB:3PP0}.
FT   HELIX       949    958       {ECO:0000244|PDB:3PP0}.
FT   HELIX       963    965       {ECO:0000244|PDB:3PP0}.
FT   HELIX       969    980       {ECO:0000244|PDB:3PP0}.
FT   HELIX       983    986       {ECO:0000244|PDB:3PP0}.
FT   HELIX       989    992       {ECO:0000244|PDB:3PP0}.
FT   HELIX      1003   1007       {ECO:0000244|PDB:3PP0}.
FT   STRAND     1140   1142       {ECO:0000244|PDB:1MW4}.
SQ   SEQUENCE   1255 AA;  137910 MW;  39E9DFDA04DCF962 CRC64;
     MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL
     ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG
     DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA
     LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC
     AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
     YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN
     IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP
     DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV
     PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC
     VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
     PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG
     ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL
     RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP
     YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR
     LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT
     HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM
     IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA
     EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG
     AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV
     NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
     GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV
//
